These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 27390695

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R, Lai MC, Beswick A, Gorman DA, Anagnostou E, Szatmari P, Anderson KK, Ameis SH.
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [Abstract] [Full Text] [Related]

  • 6. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.
    Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW.
    J Atten Disord; 2011 Nov; 15(8):674-83. PubMed ID: 20837981
    [Abstract] [Full Text] [Related]

  • 7. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
    Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V.
    J Psychopharmacol; 2016 May; 30(5):444-58. PubMed ID: 27005307
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, García-Polavieja MJ, Gilaberte I, Escobar R.
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [Abstract] [Full Text] [Related]

  • 10. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 11. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
    Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K, SUNBEAM Study Group.
    Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
    [Abstract] [Full Text] [Related]

  • 12. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR.
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [Abstract] [Full Text] [Related]

  • 13. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
    Zheng Y, Wang YF, Qin J, Wang LW, Zou LP, Jin XM, Xu T, Wang Y, Qi YL, Gong ME, Yin QY, Mai JN, Jing J, Luo XY, Ma HW, Li HB, Xie L, Li Y, Kuang GF, Yi MJ, Wang F, Zhu XH, Yao YB.
    Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L.
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
    Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D.
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801
    [Abstract] [Full Text] [Related]

  • 18. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [Abstract] [Full Text] [Related]

  • 19. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Feb; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 20. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
    Starr HL, Kemner J.
    J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.